Comparison of gemcitabine plus nab-paclitaxel and FOLFIRINOX in metastatic pancreatic cancer

BACKGROUND: Gemcitabine plus nab-paclitaxel (GA) and modified FOLFIRINOX (FFX) have been widely used as standard first-line treatment in pancreatic cancer. However, it is unclear which regimen is more efficacious. AIM: To evaluate a retrospective analysis comparing the efficacy and safety of FFX and...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Sung Yong, Kim, Dong Uk, Seol, Young Mi, Kim, Suk, Lee, Nam Kyung, Hong, Seung Baek, Seo, Hyung-Il
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2020
Materias:
Retrospective Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479547/
https://www.ncbi.nlm.nih.gov/pubmed/32953848
http://dx.doi.org/10.12998/wjcc.v8.i17.3718

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7479547/
https://www.ncbi.nlm.nih.gov/pubmed/32953848
http://dx.doi.org/10.12998/wjcc.v8.i17.3718

Ejemplares similares